{"id":64157,"date":"2026-07-07T19:50:00","date_gmt":"2026-07-07T12:50:00","guid":{"rendered":"https:\/\/thaipropertynews.com\/feeds\/?p=64157"},"modified":"2026-07-07T19:50:00","modified_gmt":"2026-07-07T12:50:00","slug":"piramal-pharmas-fy2026-annual-report-showcases-global-scale-innovation-led-growth-and-sustainability-milestones","status":"publish","type":"post","link":"https:\/\/thaipropertynews.com\/feeds\/?p=64157","title":{"rendered":"Piramal Pharma&#8217;s FY2026 Annual Report showcases global scale, innovation-led growth and sustainability milestones"},"content":{"rendered":"<table border=\"0\" cellspacing=\"10\" cellpadding=\"5\" align=\"right\">\n<tbody>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mmx.prnasia.com\/media\/MS1362699\/Piramal-Pharma-Limited-Logo.jpg?id=OA2753116&amp;p=medium600\" border=\"0\" alt=\"\" title=\"logo\" hspace=\"0\" vspace=\"0\" width=\"118\" \/><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><span class=\"legendSpanClass\">MUMBAI, India<\/span>, <span class=\"legendSpanClass\">July 7, 2026<\/span> \/PRNewswire\/ &#8212;\u00a0Piramal Pharma Limited (PPL) (NSE: PPLPHARMA) (BSE: 543635), a leading global pharmaceutical, health and wellness company, released its Annual Report for FY2026, highlighting a year of strengthening its global platform, investing in differentiated capabilities, advancing sustainability, and delivering quality across operations. The report reflects Piramal Pharma&#8217;s continued commitment to improving patient outcomes through science-led innovation, operational excellence and quality, while building a resilient global platform that serves customers across regulated markets worldwide.<\/p>\n<div class=\"PRN_ImbeddedAssetReference\">\n<p> <a href=\"https:\/\/mmx.prnasia.com\/media\/MS1878763\/Annual-Report-FY27-Infographic.jpg?id=OA2753115&amp;p=medium600\" target=\"_blank\"><img decoding=\"async\" src=\"https:\/\/mmx.prnasia.com\/media\/MS1878763\/Annual-Report-FY27-Infographic.jpg?id=OA2753115&amp;p=medium600\" title=\"Piramal Pharma&apos;s FY2026 Annual Report\" alt=\"Piramal Pharma&apos;s FY2026 Annual Report\" \/><\/a><br \/><span>Piramal Pharma&#8217;s FY2026 Annual Report<\/span><\/p>\n<\/div>\n<p>During FY2026, Piramal Pharma reported revenue from operations of <b>\u20b98,869 crore<\/b>, supported by a diversified business model with 17 global development and manufacturing facilities, commercial presence across more than 100 countries. Approximately <b>66% of the Company&#8217;s revenue was generated from regulated markets<\/b>, reinforcing its strong global footprint.<\/p>\n<p><b>Ms. Nandini Piramal, Chairperson of Piramal Pharma Limited, said,<\/b> <i>&#8220;FY2026 was a transitional year, shaped by external disruptions and certain business-specific factors. Despite these challenges, we exited the year on a stronger note across three businesses with improved execution and better visibility of future growth.&#8221;<\/i><\/p>\n<p><b>Key Highlights from the report:<\/b><\/p>\n<ul type=\"disc\">\n<li>Piramal Pharma Solutions (CDMO), which contributed <b>55% of the Company&#8217;s revenue<\/b>, continued to strengthen its position as a leading integrated global CDMO, supporting <b>over 500 global customers<\/b> across the pharmaceutical and biotechnology ecosystem. During the year, the Company also continued strategic investments, including a commitment of <b>US$90 million expansion<\/b> in sterile injectables and payload linker capabilities<\/li>\n<li>Piramal Critical Care (CHG) further strengthened its leadership in US inhaled anesthesia market, retaining its <b>No. 1 position in the US Sevoflurane market. Further, it completed the acquisition<\/b> of Kenalog, while continuing to serve <b>over 6,000 hospitals, surgical centres and clinics globally<\/b><\/li>\n<li>Piramal Consumer Healthcare delivered <b>\u20b91,274 crore<\/b> in revenue and continued to strengthen its portfolio of over <b>25 consumer brands<\/b>. The business launched <b>31 new products and SKUs<\/b> during FY2026, while its Power Brands recorded <b>24% growth<\/b>, contributing <b>52% of overall Consumer Healthcare revenue<\/b><\/li>\n<li>Quality remained a cornerstone of the Company&#8217;s operations. During FY2026, Piramal Pharma successfully completed <b>38 regulatory inspections, including three USFDA inspections. We continue to maintain our status of zero Official Action Indicated (OAI) observations across all USFDA inspections<\/b>, reinforcing the strength of PPL&#8217;s quality systems and compliance standards<\/li>\n<li>The Company also continued to advance its sustainability agenda, achieving a <b>22.6% reduction in Scope 1 and Scope 2 greenhouse gas emissions compared with the FY2022 baseline<\/b>, following the approval of its science-based decarbonisation roadmap<\/li>\n<li>Piramal Pharma continued to strengthen its people first culture, with a global workforce of <b>over 7,285 employees<\/b>, while maintaining its strong commitment to workplace safety by achieving <b>zero fatalities for the fifth consecutive year<\/b><\/li>\n<\/ul>\n<p><b>For additional business highlights and key performance metrics, please refer to the accompanying FY2026 infographic.<\/b><\/p>\n<p>For more information, please refer to the full report available at <a href=\"https:\/\/ppl-da-website-new-afd-endpoint-bgd4d0c9egf9g2eq.a01.azurefd.net\/media\/documents\/Annual-Report-FY-2025-26.pdf\" target=\"_blank\" rel=\"nofollow\">https:\/\/ppl-da-website-new-afd-endpoint-bgd4d0c9egf9g2eq.a01.azurefd.net\/media\/documents\/Annual-Report-FY-2025-26.pdf<\/a><\/p>\n<p><b>About Piramal Pharma Limited<\/b><\/p>\n<p>Piramal Pharma Limited (PPL, NSE: PPLPHARMA) (BSE: 543635), offers a portfolio of differentiated products and services through its 17* global development and manufacturing facilities and a global distribution network in over 100 countries.\u00a0PPL includes Piramal Pharma Solutions (PPS), an integrated contract development and manufacturing organization; Piramal Critical Care (PCC), a complex hospital generics business; and Piramal Consumer Healthcare business, selling wellness products across consumer healthcare categories. In addition, one of PPL&#8217;s associate companies, Abbvie Therapeutics India Private Limited, a joint venture between Abbvie and PPL, has emerged as one of the market leaders in the ophthalmology therapy area in the Indian pharma market. Further, PPL has a strategic minority investment in Yapan Bio Private Limited, that operates in the biologics\/bio-therapeutics and vaccine segments.<\/p>\n<p>For more information, visit:\u00a0<a href=\"https:\/\/www.piramalpharma.com\/\" target=\"_blank\" rel=\"nofollow\">Piramal Pharma<\/a> |\u00a0<a href=\"https:\/\/in.linkedin.com\/company\/lifeatpiramalpharma\" target=\"_blank\" rel=\"nofollow\">LinkedIn<\/a><\/p>\n<p><sup>* Includes one facility via\u00a0PPL&#8217;s minority investment in Yapan Bio.<\/sup><\/p>\n<p>\u00a0<\/p>\n<div class=\"PRN_ImbeddedAssetReference\">  <\/div>","protected":false},"excerpt":{"rendered":"<p><!-- wp:html --><\/p>\n<table border=\"0\" cellspacing=\"10\" cellpadding=\"5\" align=\"right\">\n<tbody>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mmx.prnasia.com\/media\/MS1362699\/Piramal-Pharma-Limited-Logo.jpg?id=OA2753116&amp;p=medium600\" border=\"0\" alt=\"\" title=\"logo\" hspace=\"0\" vspace=\"0\" width=\"118\" \/><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><span class=\"legendSpanClass\">MUMBAI, India<\/span>, <span class=\"legendSpanClass\">July 7, 2026<\/span> \/PRNewswire\/ &#8212;\u00a0Piramal Pharma Limited (PPL) (NSE: PPLPHARMA) (BSE: 543635), a leading global pharmaceutical, health and wellness company, released its Annual Report for FY2026, highlighting a year of strengthening its global platform, investing in differentiated capabilities, advancing sustainability, and delivering quality across operations. The report reflects Piramal Pharma&#8217;s continued commitment to improving patient outcomes through science-led innovation, operational excellence and quality, while building a resilient global platform that serves customers across regulated markets worldwide.<\/p>\n<div class=\"PRN_ImbeddedAssetReference\">\n<p> <a href=\"https:\/\/mmx.prnasia.com\/media\/MS1878763\/Annual-Report-FY27-Infographic.jpg?id=OA2753115&amp;p=medium600\" target=\"_blank\"><img decoding=\"async\" src=\"https:\/\/mmx.prnasia.com\/media\/MS1878763\/Annual-Report-FY27-Infographic.jpg?id=OA2753115&amp;p=medium600\" title=\"Piramal Pharma&apos;s FY2026 Annual Report\" alt=\"Piramal Pharma&apos;s FY2026 Annual Report\" \/><\/a><br \/><span>Piramal Pharma&#8217;s FY2026 Annual Report<\/span><\/p>\n<\/div>\n<p>During FY2026, Piramal Pharma reported revenue from operations of <b>\u20b98,869 crore<\/b>, supported by a diversified business model with 17 global development and manufacturing facilities, commercial presence across more than 100 countries. Approximately <b>66% of the Company&#8217;s revenue was generated from regulated markets<\/b>, reinforcing its strong global footprint.<\/p>\n<p><b>Ms. Nandini Piramal, Chairperson of Piramal Pharma Limited, said,<\/b> <i>&#8220;FY2026 was a transitional year, shaped by external disruptions and certain business-specific factors. Despite these challenges, we exited the year on a stronger note across three businesses with improved execution and better visibility of future growth.&#8221;<\/i><\/p>\n<p><b>Key Highlights from the report:<\/b><\/p>\n<ul type=\"disc\">\n<li>Piramal Pharma Solutions (CDMO), which contributed <b>55% of the Company&#8217;s revenue<\/b>, continued to strengthen its position as a leading integrated global CDMO, supporting <b>over 500 global customers<\/b> across the pharmaceutical and biotechnology ecosystem. During the year, the Company also continued strategic investments, including a commitment of <b>US$90 million expansion<\/b> in sterile injectables and payload linker capabilities<\/li>\n<li>Piramal Critical Care (CHG) further strengthened its leadership in US inhaled anesthesia market, retaining its <b>No. 1 position in the US Sevoflurane market. Further, it completed the acquisition<\/b> of Kenalog, while continuing to serve <b>over 6,000 hospitals, surgical centres and clinics globally<\/b><\/li>\n<li>Piramal Consumer Healthcare delivered <b>\u20b91,274 crore<\/b> in revenue and continued to strengthen its portfolio of over <b>25 consumer brands<\/b>. The business launched <b>31 new products and SKUs<\/b> during FY2026, while its Power Brands recorded <b>24% growth<\/b>, contributing <b>52% of overall Consumer Healthcare revenue<\/b><\/li>\n<li>Quality remained a cornerstone of the Company&#8217;s operations. During FY2026, Piramal Pharma successfully completed <b>38 regulatory inspections, including three USFDA inspections. We continue to maintain our status of zero Official Action Indicated (OAI) observations across all USFDA inspections<\/b>, reinforcing the strength of PPL&#8217;s quality systems and compliance standards<\/li>\n<li>The Company also continued to advance its sustainability agenda, achieving a <b>22.6% reduction in Scope 1 and Scope 2 greenhouse gas emissions compared with the FY2022 baseline<\/b>, following the approval of its science-based decarbonisation roadmap<\/li>\n<li>Piramal Pharma continued to strengthen its people first culture, with a global workforce of <b>over 7,285 employees<\/b>, while maintaining its strong commitment to workplace safety by achieving <b>zero fatalities for the fifth consecutive year<\/b><\/li>\n<\/ul>\n<p><b>For additional business highlights and key performance metrics, please refer to the accompanying FY2026 infographic.<\/b><\/p>\n<p>For more information, please refer to the full report available at <a href=\"https:\/\/ppl-da-website-new-afd-endpoint-bgd4d0c9egf9g2eq.a01.azurefd.net\/media\/documents\/Annual-Report-FY-2025-26.pdf\" target=\"_blank\" rel=\"nofollow\">https:\/\/ppl-da-website-new-afd-endpoint-bgd4d0c9egf9g2eq.a01.azurefd.net\/media\/documents\/Annual-Report-FY-2025-26.pdf<\/a><\/p>\n<p><b>About Piramal Pharma Limited<\/b><\/p>\n<p>Piramal Pharma Limited (PPL, NSE: PPLPHARMA) (BSE: 543635), offers a portfolio of differentiated products and services through its 17* global development and manufacturing facilities and a global distribution network in over 100 countries.\u00a0PPL includes Piramal Pharma Solutions (PPS), an integrated contract development and manufacturing organization; Piramal Critical Care (PCC), a complex hospital generics business; and Piramal Consumer Healthcare business, selling wellness products across consumer healthcare categories. In addition, one of PPL&#8217;s associate companies, Abbvie Therapeutics India Private Limited, a joint venture between Abbvie and PPL, has emerged as one of the market leaders in the ophthalmology therapy area in the Indian pharma market. Further, PPL has a strategic minority investment in Yapan Bio Private Limited, that operates in the biologics\/bio-therapeutics and vaccine segments.<\/p>\n<p>For more information, visit:\u00a0<a href=\"https:\/\/www.piramalpharma.com\/\" target=\"_blank\" rel=\"nofollow\">Piramal Pharma<\/a> |\u00a0<a href=\"https:\/\/in.linkedin.com\/company\/lifeatpiramalpharma\" target=\"_blank\" rel=\"nofollow\">LinkedIn<\/a><\/p>\n<p><sup>* Includes one facility via\u00a0PPL&#8217;s minority investment in Yapan Bio.<\/sup><\/p>\n<p>\u00a0<\/p>\n<div class=\"PRN_ImbeddedAssetReference\">  <\/div>\n<p><!-- \/wp:html --><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":[],"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[5,7],"tags":[],"class_list":["post-64157","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-cision-pr-newswire","category-cision-pr-newswire-en"],"_links":{"self":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/64157","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=64157"}],"version-history":[{"count":0,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/64157\/revisions"}],"wp:attachment":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=64157"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=64157"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=64157"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}